Compelo Medical Devices is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More
Close
Dismiss

MolecularMD develops Notch1 NGS test to support clinical development for OncoMed’s anti-Notch1 antibody

MolecularMD, a molecular diagnostics company that provides custom companion diagnostic solutions and supporting clinical trial services for targeted cancer therapies, in collaboration with OncoMed Pharmaceuticals, will present the development and validation of a proprietary Notch1 Next Generation DNA Sequencing (NGS) test at the upcoming 19th European Hematology Association (EHA) Congress.

At the EHA, MolecularMD and OncoMed will present the validation studies for the proprietary Notch1 NGS assay being developed to identify Notch1 mutation status in patients with certain hematologic malignancies.

Notch1 mutations have been linked to more refractory lymphoid malignancies, such as chronic lymphocytic leukemia, mantle cell lymphoma, and others, putting patients at greater risk for poor outcomes and reduced overall survival.

The MolecularMD Notch1 NGS Assay is being developed as a companion diagnostic to identify patients whose cancer may be more likely to benefit from treatment with OncoMed’s anti-Notch1 antibody, OMP-52M51, currently in Phase I clinical studies.